The disclosure provides hydrogel compositions comprising polysaccharides with repeat units and methods of synthesis and usage.

The present invention relates to a drug eluting device for preventing and treating restenosis and neointimal formation after vascular procedures and/or implantation of implants comprising an implantable or non-implantable device, such as stent, balloon or graft containing an effective amount of at least one retinoid receptors ligand as active ingredient and a coating system.

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.

Biocompatible copolymers and thermo-responsive hydrogels formed from the copolymers are disclosed. The biocompatible copolymers include monomers comprising polysaccharides or derivatives thereof, therapeutic agents or derivatives thereof and thermo-responsive monomers and are cross-linked with an acrylamide-containing crosslinker. The hydrogels are used as implant materials to treat or prevent joint damage or osteoarthritis in a subject.

Devices, bandages, kits and methods are described that can control or regulate the mechanical environment of a wound to ameliorate scar and/or keloid formation. The mechanical environment of a wound includes stress, strain, and any combination of stress and strain. The control of a wound's mechanical environment can be active, passive, dynamic, or static. The devices are configured to be removably secured to a skin surface in proximity to the wound site and shield the wound from endogenous and/or exogenous stress.

Medical devices are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Compositions and methods of using same for tissue regeneration are provided. Accordingly, there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and Copolymer 1 at a concentration range of 10-150 microgram/ml. Also provided is a composition comprising a hyaluronic acid, a laminin polypeptide and vitamin E at a concentration range of 0.3-30 mM. Also provided are matrices and hydrogels of the compositions and methods of using same.

Deferred treatment of nerve injuries is provided. Accordingly, there is provided a method of deferred treatment of a nerve injury in a subject in need thereof, the method comprising implanting at least 1 week following onset or diagnosis of the nerve injury in the subject a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant at or near the nerve injury of the subject.

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen yeast and c: Penicillium).

a) Escherichia coli (additionally silver (“Ag”) as control),
b) Candida parapsilosis,
c) Penicillium notatum.